Reimagining Cancer Detection with the Power of Midbody Remnants
eMBR Genomics stands at the forefront of MBR development to establish non-invasive multi-cancer early detection through liquid biopsy. The company is dedicated to revealing the untapped potential of these crucial cellular structures in advancing next-generation diagnostics and therapeutics.
Led by world-renowned experts, we are developing innovative tools that could revolutionize cancer screening to save lives.
Our Science
MBRs are small, RNA-packed extracellular vesicles released during mitosis, otherwise known as cell division. Once dismissed as leftover debris, they’re now recognized as powerful communicators—containing essential mRNA that may influence cell fate, cancer progression, and beyond. MBRs not only signal the presence of cancer, but can also pinpoint its type. This discovery could revolutionize early multi-cancer detection and usher in a new era of personalized diagnostics and treatment.
MBRs offer significant advantages over current liquid biopsy technologies, including their larger size (1000-4000X larger than exosomes by volume), rich tissue-specific biological cargo, and production by actively dividing cells rather than dying cells, as in the case of circulating tumor DNA.
Proprietary Antibodies: Our team has developed a cutting-edge antibody to detect MBRs and isolate critical information. Accelerate your research—visit our MKLP product page to explore MBR detection solutions today. Products are available for purchase today through our partner Axio BioPharma.
Our Approach
Research & Discovery
In 2004, co-founder Dr. Skop pioneered proteomic and genomic approaches to identify novel cell division proteins using biochemically purified midbodies. Her lab has since discovered that the midbody is a translationally active RNA-containing organelle.
We collaborate with top scientists, using their decades of experience to refine our detection methods and validate the role of MBRs in the human body.


Partnership & Scale
We believe in the power of people where collaboration drive the best outcomes. So we team up with leaders in rare diseases, laboratories, and industry leaders to bring these diagnostics to market quickly and affordably.
About eMBR
eMBR Genomics unites top scientific innovators in a culture of creative collaboration. By fostering diverse perspectives and open dialogue, we accelerate breakthroughs in the use and understanding of MBRs.
Our Team

Dr. Ahna Skop, PhD
Co-Founder & CSO, Prof. Genetics, UW-Madison

Mr. Roman Gelman, MS
Co-Founder & CEO

Dr. Gene Yeo, PhD, MBA
Co-Founder & CGO, Prof. Cell & Molecular Medicine, UC-San Diego
Dr. Gene Yeo is the Sanford Stem Cell Institute Endowed Chair and Professor of Cellular and Molecular Medicine at the University of California San Diego (UCSD), specializing in RNA biology, neurodegeneration and RNA-based therapeutics, with a Ph.D. in Computational Neuroscience from MIT and an MBA from UCSD. Dr. Yeo is Director of UCSD’s Center for RNA Technologies and Therapeutics and Chief Scientist of Sanford Laboratories for Innovative Medicines, and has co-founded biotech companies including Eclipse Bioinnovations, Orbital Therapeutics, Proteona and Locana.

Dr. Mike Moser, PhD
Chief R&D Officer, Cellular Biologist
Dr. Michael J. Moser is the Chief of Research & Development at eMBR Genomics, Inc., a globally recognized expert in molecular biology and biotechnology, with a Ph.D. in Biochemistry from the University of Washington; he has pioneered the development and commercialization of molecular diagnostics and novel influenza vaccine platforms, holds multiple patents, and has contributed to Phase I and II clinical trials while focusing on innovative solutions to improve human health and well-being.

Dr. Pippa Cosper, MD, PhD
Chief Medical Officer, Prof. Oncology, UW-Madison
Dr. Pippa Cosper, MD, PhD, is the Chief Medical Officer at eMBR Genomics, Inc., with a distinguished background in radiation oncology and molecular biology; she earned her MD and PhD from the University of Colorado and a BS in Biochemistry from the University of Texas at Austin, and her research focuses on leveraging chromosomal instability to increase the therapeutic efficacy of cancer treatments.

Dr. Justin Wolter, PhD
Chief Neurological Officer, Prof. Genetics, UW-Madison
Dr. Justin Wolter, PhD, is the Chief Neurological Officer at eMBR Genomics, Inc., and an Assistant Professor of Medical Genetics at the University of Wisconsin–Madison. He specializes in neurodevelopmental and neurodegenerative disorders, focusing on how genetic diversity influences brain function and disease. Dr. Wolter performed his post-doctoral training at the University of North Carolina Chapel Hill, earned a PhD in Molecular Biology from Arizona State University, and a BS in Psychology from Utah State University. His research utilizes induced pluripotent stem cell (iPSC) and mouse models to investigate genetic modifiers of neural development, aiming to uncover mechanisms underlying neurological disorders and identify potential therapeutic targets.
eMBR Advisors

Dr. Richard Burgess, PhD
Prof. Emeritus of Oncology, UW-Madison

Dr. Michael Sussman, PhD
Co-Founder & CEO
Dr. Michael R. Sussman, PhD, is an advisor to eMBR Genomics, Inc, and a Professor of Biochemistry at the University of Wisconsin–Madison and the Salm-Bray Distinguished Chair in the College of Agricultural and Life Sciences. A pioneer in genomic technologies, he co-founded NimbleGen Systems Inc. (now Roche-NimbleGen), which developed advanced “gene chips” for DNA analysis, and Immuto Scientific, an early-stage company utilizing novel techniques to analyze protein structures. Dr. Sussman’s research focuses on signal transduction in eukaryotes, development of genomic technologies, and the study of plasma membrane receptors and ion transporters, contributing significantly to advancements in biotechnology and molecular biology.

Dr. Christina Kendziorski, PhD
Prof. Biostatistics & Genetics, UW-Madison

Join Us
We’re looking for partners, investors, and industry allies to help us transform the landscape of cancer detection. Together, we can accelerate the path to early interventions and better outcomes in human health.
Contact us to learn how you can get involved in advancing MBR-based diagnostics.